Supplementary Figure 1. Topical ozone therapy does not change the
differentiated proportion of Th1, Th2 and Treg subsets

Proportions of Th1 (a), Th2 (b), and T\textsubscript{reg} (c) cells from mouse spleens and lymph nodes were assessed by flow cytometry in four groups, e.g. Ctrl, IMQ, IMQ+Vehicle, and IMQ+Ozone.

Note: * = \( P < 0.05 \); ** = \( P < 0.01 \); *** = \( P < 0.001 \); NS = no statistical significance.
**Supplementary Table 1. Clinical information of enrollees**

| No. | Age (years) | Gender | PASI score Before treatment | 1 week after treatment | 2 weeks after treatment |
|-----|-------------|--------|----------------------------|------------------------|------------------------|
| 1   | 35          | Male   | 8.2                        | 6.1                    | 5.0                    |
| 2   | 42          | Male   | 26.5                       | 14.9                   | 12.6                   |
| 3   | 26          | Male   | 8                          | 5.6                    | 6.6                    |
| 4   | 51          | Male   | 25                         | 16.5                   | 12.4                   |
| 5   | 24          | Male   | 12.4                       | 10.2                   | 8.0                    |
| 6   | 40          | Male   | 12                         | 7.5                    | 5.0                    |
| 7   | 34          | Female | 22.5                       | 17.2                   | 10.5                   |
| 8   | 49          | Male   | 19                         | 16.5                   | 16.0                   |
| 9   | 28          | Female | 18                         | 12.4                   | 9.8                    |
| 10  | 22          | Female | 24                         | 15.6                   | 10.9                   |

**Supplementary Table 2. Primer sequences for quantitative PCR.**
H-IL17A-F: 5′-ATTACTACAACCGATCCACCTC-3′
H-IL17A-R: 5′-TGGTAGTCCACGGTCCCCT-3′
H-IL17F-F: 5′-AGTAAAGCCACCAGGCCAACATG-3′
H-IL17F-R: 5′-CTCAGAAAGGGAAGCGTCCAAATA-3′
H-IL6-F: 5′-AATTCGGTACATCCTCGACGGC-3′
H-IL6-R: 5′-GCCAGTGCTCCTTTGGCTGCTT-3′
H-TNFα-F: 5′-GGACACCATGAGCACTGAAAGC-3′
H-TNFα-R: 5′-TGCCACGATCAGGAAGGAGAAG-3′
H-TGFβ-F: 5′-GGACACCATGAGCACTGAAAGC-3′
H-TGFβ-R: 5′-TGCCACGATCAGGAAGGAGAAG-3′
H-IFNγ-F: 5′-CATCCAAAAGAGGTGGAGAC-3′
H-IFNγ-R: 5′-TGCTTTGCGTTGGACATTCAAG-3′
H-IL10-F: 5′-AAGACCCAGACATCAAGGCG-3′
H-IL10-R: 5′-AGGCATTCTTCACCTGCTCC-3′
H-P65-F: 5′-AGGGAAATGCCTCTGTGAGCT-3′
H-P65-R: 5′-GCAAGAAAGAAGAGGGTTTGA-3′
H-P50-F: 5′-AGGCCATTCAGTACGTGGTGGA-3′
H-P50-R: 5′-CGTGCGGTTGGCTAGCATTGAAC-3′
H-RORC-F: 5′-AGGCCATTCAGTACGTGGTGGA-3′
H-RORC-R: 5′-CGTGCGGTTGGCTAGCATTGAAC-3′
H-GAPDH-F: 5′-ATGGGGAAGGTGAAGGTCG-3′
H-GAPDH-R: 5′-GGGGTCATTGATGGCAACAATA-3′
M-Il17a-F: 5′-ATGCTGTTGCTGCTGCTGAG-3′
M-Il17a-R: 5′-GGAAGTCCTTGGCCTCAGTG-3′
M-Il17f-F: 5′-GGAGGTAGCAGCTCGGAAGA-3′
M-Il17f-R: 5′-GGAGCGGTTCTGGAATTCAC-3′
M-IL10-F: 5′-CTTACTGACTGGCATGAGGA-3′
M-IL10-R: 5′-CTTACTGACTGGCATGAGGA-3′
M-IFNγ-F: 5′-AGACAATCAGGCCATCAGCA-3′
M-IFNγ-R: 5′-CAACAGCTGGTGACCAACTC-3′
M-RORc-F: 5′-GGACAGGGAGCCAAGTTCTCA-3′
M-RORc-R: 5′-CACAGGTGATAACCCCGTAGTGG-3′
M-STAT3-F: 5′-GTGGGAGCAGCTCTTTCAAG-3′
M-STAT3-R: 5′-GCATGTCTCCTTGCTCTTG-3′
M-P50-F: 5′-ATGGTGGTTGGCTTTGCAAA-3′
M-P50-R: 5′-TGCACCAGAAGTCCAGGATT-3′
M-P65-F: 5′-TCATCGAAGCCGAGAAACC-3′
M-P65-R: 5′-CAGCCCATAGGGAACCTCAAC-3′
M-CXCL1-F: 5′-GACACCCGCAACTGGA-3′
M-CXCL1-R: 5′-TGACAGGGCGACTCAATG-3′
M-CXCL2-F: 5′-AAAATCATCCAAAAAGATACTGAAC-3′
M-CXCL2-R: 5′-CTTTGGTCTTCAGCGTTAGG-3′
| Primer Set | Forward Primer Sequence | Reverse Primer Sequence |
|------------|-------------------------|-------------------------|
| M-GAPDH-F  | 5'-ATGGTGAAGGTCGGTGTA-3' | M-GAPDH-R: 5'-AATCTCCAACTTGGCACTGC-3' |
| M-IL17c-F  | 5'-CCTCTAGCTGGAACACAGTGC-3' | M-IL17c-R: 5'-GCCTACCGTCTACTGTTG-3' |
| M-IL22-F   | 5'-TGACGACCAGAACATCCAGA-3' | M-IL22-R: 5'-AATCGGCTTTAGATTCCAT-3' |
| M-IL6-F    | 5'-GCTACCAAACCTTGGATAATTCAGGA-3' | M-IL6-R: 5'-GCCCAAGCCTGCTACTTCCAGA-3' |
| M-S100A8-F | 5'-TCCTTCTGGGTGATGAAAAA-3' | M-S100A8-R: 5'-GCGGTTCTCATCTGTGTCG-3' |
| M-S100A9-F | 5'-GACCCCTCTGACACCCTAGAAGG-3' | M-S100A9-R: 5'-GCGGTTCTCATCTGTGTCG-3' |
| M-TNF-α-F  | 5'-CTGTAGCCCACGTCGGTGTA-3' | M-TNF-α-R: 5'-TTGAGATCCATGCCGTTG-3' |
| M-VEGF-F   | 5'-AAAACGAAAGCGCAAGAAA-3' | M-VEGF-R: 5'-TTTCTCCTGCTCTGAACAGA-3' |
| M-CXCL3-F  | 5'-GCCAGGCCGCTTGATGAAAAA-3' | M-CXCL3-R: 5'-GCCCAAGCCTGCTACTTCCAGA-3' |
| M-IL1β-F   | 5'-GAAATGCCACCTTGGACAGG-3' | M-IL1β-R: 5'-GCCCAAGCCTGCTACTTCCAGA-3' |
| M-IL8-F    | 5'-TGCTCAAGGCTTGCCCAT-3' | M-IL8-R: 5'-GCCCAAGCCTGCTACTTCCAGA-3' |
| M-defensinB14-F | 5'-GCCCTCATTTGACAGACAC-3' | M-defensinB14-R: 5'-GCCCAAGCCTGCTACTTCCAGA-3' |
| M-S100A7-F | 5'-GCCCTCATTTGACAGACAC-3' | M-S100A7-R: 5'-GCCCAAGCCTGCTACTTCCAGA-3' |
| M-K10-F    | 5'-GCCCTCATTTGACAGACAC-3' | M-K10-R: 5'-GCCCAAGCCTGCTACTTCCAGA-3' |
| M-Filaggrin-F | 5'-GCCCTCATTTGACAGACAC-3' | M-Filaggrin-R: 5'-GCCCAAGCCTGCTACTTCCAGA-3' |
| M-Loricrin-F | 5'-GCCCTCATTTGACAGACAC-3' | M-Loricrin-R: 5'-GCCCAAGCCTGCTACTTCCAGA-3' |

Note: H = human; M = mouse; F = forward primer; and R = reverse primer.